

PROGRAM

11 NOVEMBER 2026




Conference Venue:

Masaryk Student Dormitory
Congress Centre
Thákurova 550/1
Prague 6 - Dejvice, 160 00



Scientific Guarantor:

Assoc. Prof. Miloš Bohoněk, MD, PhD



Held under the auspices of Brigadier General Michal Baran, MD
Director of the Military Health Section of the MoD



The conference is registered with the Czech Medical Chamber in accordance with ČLK Regulation No. 16.



Simultaneous interpretation into English and Czech will be provided at the conference.

7:30 – 9:30 REGISTRATION

9:30 – 9:40 OPENING CEREMONY

SESSION 1: POST-TRANSFUSION REACTIONS AND COMPLICATIONS

9:40 – 10:00 Hemovigilance in the Czech Republic: How Are We Doing in Numbers?

Galuszková Dana

Transfusion Department, University Hospital Olomouc

10:00 – 10:20 Hemovigilance from the Perspective of Public Domestic and International Databases

Krätzerová Lucie, Kutáč Dominik

Institute of Laboratory Medicine, Hematology and Transfusiology FBME

CTU and UVN, Military University Hospital Prague

10:20 – 10:40 Root Cause Analysis as a Tool for Managing Serious Adverse Events in Hemotherapy

Kavanová Zdeňka, Procházková Renata

Transfusion Department, Regional Hospital Liberec

10:40 – 11:00 Fatal Reaction Following Plasma Transfusion: A Case Report

Kutáč Dominik

Institute of Laboratory Medicine, Hematology and Transfusiology FBME

CTU and UVN, Military University Hospital Prague

11:00 – 11:10 Discussion

11:10 – 11:40 Break

SESSION 2: SAFETY OF PLASMA DONORS

11:40 – 12:00 Plasma Donor Safety: Focus on PPTA studies

Wetzel Alexa

PPTA, Brussels, Belgium



- 12:00 – 12:20** **Experience with Personalized Plasmapheresis in the US
– Recent trials and real-world data**
Hartmann Jan
Haemonetics, Boston, USA
- 12:20 – 12:40** **RESPECT-P (Retrospective Study on the Impact of Plasma
Donation on Healthy Donors) – Preliminary Results**
Bohoněk Miloš et al.
*Institute of Laboratory Medicine, Hematology and Transfusiology FBME
CTU and UVN, Military University Hospital Prague*
- 12:40 – 12:50** **Discussion**
- 12:50 – 14:00** **Lunch**

SESSION 3: ASSESSMENT OF BLOOD DONOR ELIGIBILITY AND ELIGIBILITY OF BLOOD COMPONENT DONORS

- 14:00 – 14:15** **Blood Donations from Whole-Blood Donors Over the Age of 65**
Turek Petr
Thomayer University Hospital Prague
- 14:15 – 14:30** **Prevention of Iron Deficiency in Whole Blood Donors
in the Czech Republic**
Turek Petr, Řeháček Vít, Masopust Jiří, Procházková Renata
Thomayer University Hospital Prague
- 14:30 – 14:50** **Psychotropic Medications in Blood Donors – Current Approach
to Donor Eligibility Assessment**
Vanková Vanda
Transfusion and Tissue Department, University Hospital Brno
- 14:50 – 15:10** **Assessment of Blood Donor Eligibility in the Era of Modern
Diabetes and Obesity Therapies**
Procházková Renata, Papoušek Petr
Transfusion Department, Regional Hospital Liberec
- 15:10 – 15:20** **Discussion**
- Closing of the Conference**

**Dr. med. Jan Hartmann**

Senior Vice President, Chief Medical Officer
Haemonetics Corp.



Jan Hartmann, M.D. is Senior Vice President and Chief Medical Officer at Haemonetics Corporation, a role he has held since April 2023. Since joining the company in 2016, he has led its global Medical Affairs and Clinical Development organizations and served as Medical Safety Officer.

Dr. Hartmann has extensive expertise in coagulation, viscoelastic testing, and plasma collection technologies. He

led the clinical development supporting the introduction of the first personalized plasmapheresis nomogram in the United States and has advanced the use of real-world data to characterize the safety profile of plasma donation at scale. His work also focuses on the future application of personalized approaches to plasma collection in Europe.

Prior to Haemonetics, Dr. Hartmann was an Associate Partner at McKinsey & Company in the Pharmaceuticals and Medical Devices Practice, advising on clinical strategy and medical affairs across multiple therapeutic areas, including hematology and respiratory medicine.

He received his medical degree from the University of Munich, holds a doctorate in medicine from the University of Freiburg, and was a research scholar at Yale University School of Medicine.

Alexa Wetzel

Senior Director, Lead for European Plasma
Plasma Protein Therapeutics Association (PPTA)



Alexa Wetzel is Senior Director and Lead for European Plasma at the Plasma Protein Therapeutics Association (PPTA). Since joining PPTA in 2010, she has worked at the intersection of plasma collection, health policy, and stakeholder engagement across Europe and internationally. She coordinates the European Plasma Alliance (EPA), representing plasma collectors in Germany, Austria, Czechia, Hungary, and Ukraine in their

dialogue with European and national institutions. Her work also extends to initiatives in France, cross-industry collaboration on sustainability, and, more recently, international projects involving China.

Originally from Belgium's German-speaking community and now based in Brussels, Alexa brings an international perspective to her work. She holds a Bachelor's degree in Marketing and a Master's degree in Linguistics and Translation Sciences.